Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Caitlin John LLC

Caitlin John LLC lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 1,850.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,872 shares of the company’s stock after purchasing an additional 1,776 shares during the period. Caitlin John LLC’s holdings in Pacira BioSciences were worth $35,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC boosted its position in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after purchasing an additional 2,749 shares during the period. Virtus Investment Advisers Inc. purchased a new stake in Pacira BioSciences during the 3rd quarter worth $98,000. CWM LLC boosted its position in Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after purchasing an additional 5,716 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock worth $134,000 after purchasing an additional 3,404 shares during the period. Finally, Quest Partners LLC boosted its position in Pacira BioSciences by 137.6% during the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock worth $142,000 after purchasing an additional 5,449 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $26.26 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.67. The company’s 50-day simple moving average is $20.81 and its 200-day simple moving average is $17.84. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -12.94 and a beta of 0.80.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PCRX. Barclays decreased their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Needham & Company LLC upped their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and a consensus price target of $26.20.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.